Is Annovis Bio (ANVS) stock A Good Buy After Friday’s Big Move?

Those who are looking into stocks that might have made significant gains on Friday might consider taking a closer look at the Annovis Bio (NYSEAMERICAN:ANVS) stock.

Is Annovis Bio (ANVS) stock A Good Buy After Friday’s Big Move?

Last Friday, the stock soared by as much as 127% after the company announced that there were indications of major improvement in one of its products during a trial. The product is meant for the treatment of those suffering from Parkinson’s and Alzheimer’s. The product development by the company has apparently displayed considerable effectiveness in treating those conditions.

Related:  Is GeoVax Labs (GOVX) Stock Ready to Bounce Back in 2021?

The treatment was administered to a total of 28 patients, half of whom suffered from Alzheimer’s and the other half suffered from Parkinson’s. The treatment was administered over a period of 25 days. After the trial had concluded, it was observed that the cognitive functions of those who had been treating with the medicine had improved significantly when compared to those who had been treated with placebo. In light of these developments, it might be a good move to keep the Annovis stock on your watch list this week.

Related:  FSD Pharma (HUGE) Skyrockets Before Using FSD201 For Phase 2 Clinical Trial To Treat COVID-19 Patients

ANVS stock is down 7.41% to $55.75 in the pre-market session.

Michael Rowels

Weekend Contributor. Writing for business and finance publishers has become his passion over the last decades after he completed a master's degree in Financial Management. Sharing some opinions and forecasts to thousands of readers is a routine job for him but he never promises to invest in one stock.